How long does it take for ovulation to occur after injecting human chorionic gonadotropin?

Generally, people who want to have children can have sex by testing their ovulation status, which will increase the chance of conception. However, some women need to take medication due to physical reasons, such as injecting chorionic gonadotropin to promote ovulation. In fact, under normal circumstances, ovulation will occur within 24-48 hours after injecting chorionic gonadotropin. If you have sex during this time, the chance of a woman getting pregnant is very high.

Chorionic gonadotropin is a glycoprotein hormone produced by the placenta and extracted from the urine of pregnant women. It can stimulate gonadal activity, promote follicle maturation and ovulation in women, and promote the function of seminiferous tubules and the activity of interstitial cells in the testes in men, so as to increase the production of androgens, promote testicular descent and promote sperm production. It is commonly used for sexual dysfunction, habitual abortion, severe uterine bleeding, amenorrhea, infertility, cryptorchidism, etc., but it is ineffective for cryptorchidism caused by anatomical lesions. Chorionic gonadotropin and luteinizing hormone (LH) have the same α subunit structure. It has biological and immune activities similar to LH. When used to promote follicle maturation, large doses of injection are required to simulate the LH peak before ovulation, thereby accelerating follicle maturation and inducing ovulation. 10,000 U is commonly used for intramuscular injection, and in most cases ovulation occurs 36 to 48 hours after injection. If conditions permit, use B-ultrasound to monitor follicular development. If artificial insemination or triggered ovulation-guided sexual intercourse is performed, it should be done on the day of human chorionic gonadotropin (HCG) injection and/or the next day, and an ultrasound examination should be performed again 48 hours later to understand whether ovulation has occurred. If ovulation still does not occur, HCG injections should be repeated and timely sexual intercourse guidance should be repeated to increase the pregnancy rate.

(2) For male infertility caused by hypopituitarism, it can be used in combination with urogonadotropin. Those with long-term hypogonadotropinemia should also be treated with testosterone.

(3) For female anovulatory infertility caused by pituitary gonadotropin deficiency, this product is often used in combination with postmenopausal gonadotropin to promote ovulation after clomiphene treatment has failed.

(4) Used for in vitro fertilization to obtain multiple oocytes, it needs to be used in combination with postmenopausal gonadotropin.

(5) Female luteal insufficiency, functional uterine bleeding, threatened abortion in early pregnancy, and habitual abortion.

Note: (1) Using this product to promote ovulation may increase the rate of multiple births, causing the newborn to be immature and the risk of premature birth.

(2) Patients with prostate hypertrophy, asthma, epilepsy, heart disease, migraine, renal impairment, etc. should use it with caution.

(3) If complications such as ovarian hyperstimulation syndrome, ovarian enlargement, pleural effusion, and ascites are found, the medication should be discontinued or a doctor’s advice should be sought.

(4) The possibility of multiple pregnancies should be explained to patients before use. Inquire about adverse reactions during use and conduct relevant clinical examinations regularly.

(5) Pregnancy tests may show false positives and should be tested 10 days after taking the medication.

(6) Athletes and patients with hypertension should use with caution.

(7) This product should be prepared temporarily before use.

(8) Follow-up examinations should be performed during medication.

(9) This product should not be used continuously for a long time in other situations except for male gonadotropin deficiency and to promote spermatogenesis.

(10) Treatment of cryptorchidism may occasionally lead to precocious puberty, which may cause premature closure of the epiphysis and ultimately result in failure to reach adult height.